2025 ASCO Genitourinary Cancers Symposium

BIOTYPE at ASCO GU 2025 – Driving Innovation in Uro-Oncology

We’re excited to be part of the ASCO Genitourinary Cancers Symposium in San Francisco from February 13–15, 2025!

At BIOTYPE, we're committed to advancing uro-oncology diagnostics, with a strong focus on bladder cancer. Our MODAPLEX assay portfolio already enables precise detection of FGFR3 alterations, and we’re expanding it to include gene expression analysis on bladder samples, bringing even more insights for personalized treatment.

We look forward to connecting with you at ASCO GU 2025! Meet our team, Timm Zörgiebel and Vanessa Grunwald, to discuss the latest advancements in uro-oncology and explore how we can shape the future of precision diagnostics together.